<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03719326</url>
  </required_header>
  <id_info>
    <org_study_id>AB928CSP0002</org_study_id>
    <nct_id>NCT03719326</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies</brief_title>
  <official_title>A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcus Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Infinity Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arcus Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/1b, open-label, dose-escalation, and dose-expansion study to evaluate the&#xD;
      safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of&#xD;
      etrumadenant (AB928) in combination with pegylated liposomal doxorubicin (PLD) with or&#xD;
      without IPI-549 in participants with advanced metastatic triple-negative breast cancer (TNBC)&#xD;
      or ovarian cancer, and etrumadenant in combination with nanoparticle albumin-bound-paclitaxel&#xD;
      (NP) in participants with advanced metastatic TNBC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the dose escalation phase, the following will be assessed:&#xD;
&#xD;
        -  Arm A: escalating doses of etrumadenant in combination with PLD at standard doses will&#xD;
           be assessed in participants with advanced metastatic triple-negative breast cancer or&#xD;
           ovarian cancer. Eligible participants will receive oral administration of etrumadenant&#xD;
           as well as intravenous (IV) infusion of PLD. The recommended dose (RDE) for expansion&#xD;
           Arms 1 and 2 and escalation Arm C will be determined upon completion of this dose&#xD;
           escalation arm.&#xD;
&#xD;
        -  Arm B: escalating doses of etrumadenant in combination with the NP at standard doses&#xD;
           will also be assessed in participants with advanced metastatic TNBC. Eligible&#xD;
           participants will receive oral administration of etrumadenant as well as NP infusion.&#xD;
           The RDE of etrumadenant will be determined upon completion of this dose escalation arm.&#xD;
&#xD;
        -  Arm C: escalating doses of IPI-549 in combination with the RDE of etrumadenant (from Arm&#xD;
           A) and PLD at standard doses will be assessed in participants with advanced metastatic&#xD;
           TNBC or ovarian cancer. Eligible participants will receive oral administration of both&#xD;
           etrumadenant and IPI-549 as well as IV infusion of PLD. The RDE of IPI-549 for expansion&#xD;
           Arm 4 will be determined upon completion of this dose escalation arm.&#xD;
&#xD;
      In the dose expansion phase, the following will be assessed:&#xD;
&#xD;
        -  Arms 1 and 2: Etrumadenant at the RDE in combination with PLD at standard doses may be&#xD;
           assessed in participants with advanced metastatic TNBC or ovarian cancer.&#xD;
&#xD;
        -  Arm 3: Etrumadenant at the RDE in combination with NP at standard doses may be assessed&#xD;
           in participants with advanced metastatic TNBC.&#xD;
&#xD;
        -  Arm 4: Etrumadenant and IPI-549 at the RDE in combination with PLD at standard doses may&#xD;
           be assessed in participants with advanced metastatic TNBC.&#xD;
&#xD;
      Overall duration of treatment will depend on how well the treatment is tolerated. Treatment&#xD;
      may continue until unacceptable toxicity or progressive disease or other reasons specified in&#xD;
      the protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2018</start_date>
  <completion_date type="Actual">July 2, 2021</completion_date>
  <primary_completion_date type="Actual">July 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>3+3 dose escalation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>From first dose date to 30 days after the last dose (Approximately 1 year)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLTs) during the dose escalation phase</measure>
    <time_frame>From first dose date to 28 days after the first dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of etrumadenant</measure>
    <time_frame>Recorded at baseline (prior to first dose), during the first 4 cycles of treatment (4 months) and at the end of treatment (i.e. in total approximately 5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of IPI-549</measure>
    <time_frame>Recorded at baseline (prior to first dose), during the first 4 cycles of treatment (4 months) and at the end of treatment (i.e. in total approximately 5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a best overall response of Complete Response (CR) or Partial Response (PR), as determined by Investigator according to Response Evaluation in Solid Tumors (RECIST) v 1.1</measure>
    <time_frame>From study enrollment until participation discontinuation, first occurrence of progressive disease or death from any cause, whichever occurs first (approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Disease Control (complete response, partial response, or stable disease) for &gt; 6 months as determined by RECIST v1.1</measure>
    <time_frame>From study enrollment until disease progression or loss of clinical benefit (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response as determined by the Investigator according to RECIST v1.1</measure>
    <time_frame>From the date of the first occurrence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) as determined by the Investigator according to RECIST v1.1</measure>
    <time_frame>From start of the treatment up to first occurrence of progressive disease or death from any cause, whichever occurs first (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) as determined by the Investigator according to RECIST v1.1</measure>
    <time_frame>From start of treatment up to death from any cause (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of etrumadenant target inhibition in peripheral blood</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 4 Day 1 (4 months) and at the end of treatment (in total approximately 5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunophenotyping activity in select immune subsets for etrumadenant and IPI-549 in peripheral blood</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 4 Day 1 (4 months) and at the end of treatment (in total approximately 5 months).</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>TNBC - Triple-Negative Breast Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Escalation-Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation-Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation-Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion-TNBC-Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose given will be determined from the dose escalation part (Arm A).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion-Ovarian Cancer-Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose given will be determined from the dose escalation part (Arm A).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion-TNBC-Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose given will be determined from the dose escalation part (Arm B). .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion-TNBC-Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose expansion will be determined from the dose escalation part (Arm C).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etrumadenant</intervention_name>
    <description>Etrumadenant is an A2aR and A2bR antagonist for oral use</description>
    <arm_group_label>Dose Escalation-Arm A</arm_group_label>
    <arm_group_label>Dose Escalation-Arm B</arm_group_label>
    <arm_group_label>Dose Escalation-Arm C</arm_group_label>
    <arm_group_label>Dose Expansion-Ovarian Cancer-Arm 2</arm_group_label>
    <arm_group_label>Dose Expansion-TNBC-Arm 1</arm_group_label>
    <arm_group_label>Dose Expansion-TNBC-Arm 3</arm_group_label>
    <arm_group_label>Dose Expansion-TNBC-Arm 4</arm_group_label>
    <other_name>AB928</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPI-549</intervention_name>
    <description>IPI-549 is a phosphoinositide-3-kinase-gamma inhibitor for oral use</description>
    <arm_group_label>Dose Escalation-Arm C</arm_group_label>
    <arm_group_label>Dose Expansion-TNBC-Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated liposomal doxorubicin (PLD)</intervention_name>
    <description>Doxil is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous (IV) use</description>
    <arm_group_label>Dose Escalation-Arm A</arm_group_label>
    <arm_group_label>Dose Escalation-Arm C</arm_group_label>
    <arm_group_label>Dose Expansion-Ovarian Cancer-Arm 2</arm_group_label>
    <arm_group_label>Dose Expansion-TNBC-Arm 1</arm_group_label>
    <arm_group_label>Dose Expansion-TNBC-Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nanoparticle albumin-bound paclitaxel (NP)</intervention_name>
    <description>NP is a microtubule inhibitor for intravenous (IV) use</description>
    <arm_group_label>Dose Escalation-Arm B</arm_group_label>
    <arm_group_label>Dose Expansion-TNBC-Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Female participants, 18 years or older&#xD;
&#xD;
          2. Measurable disease per radiographic evaluation&#xD;
&#xD;
          3. Performance status 0 or 1&#xD;
&#xD;
          4. Available archival tissue sample (within 2 years) or a fresh tumor biopsy may be&#xD;
             required&#xD;
&#xD;
          5. Adequate organ, cardiac, and bone marrow function&#xD;
&#xD;
          6. Dose escalation&#xD;
&#xD;
               1. Participants with breast cancer:&#xD;
&#xD;
                    -  Locally advanced or metastatic triple negative breast cancer (ER-negative,&#xD;
                       PgR-negative, and HER2-negative according to ASCO/CAP guidelines) with&#xD;
                       disease progression&#xD;
&#xD;
                    -  No available alternative or curative therapy&#xD;
&#xD;
                    -  Participants may have received any number of prior therapies for&#xD;
                       advanced/recurrent and progressive disease&#xD;
&#xD;
               2. Participants with ovarian cancer:&#xD;
&#xD;
                    -  Locally advanced or metastatic ovarian cancer with disease progression&#xD;
&#xD;
                    -  No available alternative or curative therapy Participants may have received&#xD;
                       any number of prior therapies for advanced/recurrent and progressive disease&#xD;
&#xD;
          7. Dose expansion&#xD;
&#xD;
               1. Participants with breast cancer:&#xD;
&#xD;
                    -  Locally advanced or metastatic triple negative breast cancer (ER-negative,&#xD;
                       PgR-negative, and HER2-negative according to ASCO/CAP guidelines)&#xD;
&#xD;
                    -  Disease progression after no more than 3 prior lines of therapy&#xD;
&#xD;
               2. Participants with ovarian cancer:&#xD;
&#xD;
                    -  Locally advanced or metastatic ovarian cancer that is platinum-resistant&#xD;
&#xD;
                    -  Disease progression after no more than 3 prior lines of therapy&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          1. Received a live, attenuated vaccine within 4 weeks prior to first study treatment&#xD;
&#xD;
          2. Prior anticancer treatment including approved agents, systemic radiotherapy, or&#xD;
             investigational therapy within 4 weeks prior first study treatment&#xD;
&#xD;
          3. Cancer other than the disease under study within 2 years prior to study entry, except&#xD;
             for some cancers with a low risk of spreading like non-melanoma skin cancers&#xD;
&#xD;
          4. Inability to swallow oral medications&#xD;
&#xD;
          5. Participant is breastfeeding, pregnant, or expects to become pregnant during the study&#xD;
&#xD;
          6. Active autoimmune disease or documented history of autoimmune disease within 2 years&#xD;
             prior to first study treatment&#xD;
&#xD;
          7. History of peptic ulcer or stomach bleeding within 6 months prior to first study&#xD;
             treatment&#xD;
&#xD;
          8. Use of drugs contraindicated by the protocol within 4 weeks prior to and during study&#xD;
             treatment&#xD;
&#xD;
          9. Prior treatment with drugs that suppress the immune system within 2 weeks prior to&#xD;
             first study treatment&#xD;
&#xD;
         10. Presence of metastases in the brain or cancer spreading into the cerebrospinal fluid -&#xD;
             CSF (leptomeningeal disease)&#xD;
&#xD;
         11. HIV, Hepatitis B, and C test results negative prior to first study treatment&#xD;
&#xD;
         12. Major surgery within 4 weeks prior to first study treatment&#xD;
&#xD;
         13. Participants who have previously received maximum cumulative lifetime anthracycline&#xD;
             dosage or baseline ejection fraction &lt;50% (on heart echography)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Arcus Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scottsdale Healthcare Hospitals dba Honor Health Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Clinical Research Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers (Aurora)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute at Baptist Health</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, PA</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthPartners Institute Cancer Care Center</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina BioOncology Institute</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute and Research Center</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. - Austin (Midtown)</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. - Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. - Fort Worth Cancer Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. - San Antonio Northeast</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. - San Antonio Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates dba Summit Cancer Centers</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiCare Regional Cancer Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Kinghorn Cancer Centre</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. George Private Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Macquarie University</name>
      <address>
        <city>Macquarie</city>
        <state>New South Wales</state>
        <zip>2109</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pindara Private Hospital</name>
      <address>
        <city>Benowa</city>
        <state>Queensland</state>
        <zip>4217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula &amp; South Eastern Haematology and Oncology Group</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabrini Hospital</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>New Zealand</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 15, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Triple Negative Breast Cancer</keyword>
  <keyword>TNBC</keyword>
  <keyword>Ovarian Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

